The published data in a paper examining the effect of RPL554 in Cystic Fibrosis (CF) supports Verona Pharma’s development of the compound in this indication. CF is an inherited life-threatening Orphan disease with around 70,000 people afflicted worldwide. The data generated to date is encouraging and Verona plans to undertake additional studies to continue to support RPL554’s potential in CF.
